Skip navigation
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
Prevention Among Injection Drug Users
 IDU HIV Prevention

Archive archive

 IDU Home
 Fact Sheets:
 Syringe Disinfection
 Sterile Syringes
 Viral Hepatitis
 Subst. Abuse
 Criminal Justice
 Order Printed Materials
 Dear Colleague Letters
 Other Publications
 Safe Community Syringe Disposal
Explore IDU Topics
Link to a PDF document Link to a PDF document
Link to a Non-CDC site
Link to non-CDC site or document and does not necessarily represent the views of CDC
Adobe Acrobat (TM) Reader needs to be installed on your computer in order to read documents in PDF format. Download the Reader.
U.S. Department of Health and Human Services

Archival Content: 1999-2005

A Comprehensive Approach:
Preventing Blood-Borne Infections Among Injection Drug Users

Appendix A: Key Strategies for Preventing Blood-borne Pathogen Infection Among Injection Drug Users


Abdul-Quader AS, Friedman SR, Des Jarlais DC, Marmor MM, Maslansky R, Bartelme S. Methadone maintenance and behaviors in intravenous drug users that can transmit HIV. Contemporary Drug Problems 1987;14:425-433.

Academy for Educational Development (AED). Comprehensive HIV prevention services for injection drug users: an assessment of state and local technical assistance issues and priorities. Washington (DC): AED; August 1999. Prepared for the Centers for Disease Control and Prevention.

Academy for Educational Development. HIV prevention among drug users: a resource book for community planners and program managers. Washington (DC): Academy for Educational Development; 1997. Funding provided under Centers for Disease Control and Prevention contract number 200-91-0906.

American Psychological Association (APA).The effectiveness of AIDS prevention efforts. HIV prevention: state of the science. Washington (DC): Office of Technology Assessment; 1996.

Anderson JE, Cheney R, Clatts M, Faruque S, Kipke M, Long A, Mills S, Toomey K, Wiebel W. HIV risk behavior, street outreach, and condom use in eight high-risk populations. AIDS Education and Prevention 1996;8(3):191-204.

Anderson JE, Greenberg J, MacGowan R. Enhanced street outreach and condom use by high-risk populations in 5 cities. In: Greenberg J, Neuman M, editors. What have we learned from the AIDS evaluation of street outreach projects. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention; 1998:83-109.

Anglin MD, Speckart GR, Booth MW. Consequences and costs of shutting off methadone. Addictive Behaviors 1989;14(3):307-326.

Archibald CP, Ofner M, Patrick DM, Strathdee SA, Eades G, Sutherland D, Rekart ML, Schechter MT, O'Shaughnessy MV. Needle exchange program attracts high-risk injection drug users. International Conference on AIDS(Vancouver, Canada). 1996 Jul 7-12;11(1):244 (abstract no. Tu.C.320).

Ary DV, Duncan TE, Biglan A, Metzler CW, Noell JW, Smolkowski K. Development of adolescent problem behavior. Journal of Abnormal Child Psychology 1999; 27(2):141-150.

Avins AL, Lindan CP, Woods W J, Hudes ES, Boscarino JA, Kay J, et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug and Alcohol Dependence 1997;44(1):47-55.

Ball JC, Meyers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior 1988;29(3):214-226.

Battjes RJ, Pickens RW, Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected US cities. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1991;4(11):1148-1154.

Bayer R, Toomey KE. HIV prevention and the two faces of partner notification. American Journal of Public Health 1992;82(8):1158-1164.

Beardsley M, Goldstein MF, Deren S, Tortu S. Assessing intervention efficacy: an example based on change profiles of unprotected sex among drug users. Journal of Drug Issues 1996;26(3):635-648.

Beckett GA, Galena R, Shields D, Mills DA. Maine removed criminal penalties for syringe possession in 1997 after allowing sale of syringes without a prescription in 1993. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S145-S146.

Belenko S. Behind bars: substance abuse and America's prison population. New York: National Center on Addiction and Substance Abuse at Columbia University (CASA); January, 1998. www.casacolumbia.orgLink to a Non-CDC Link

Berger JM, Levin SM. Adolescent substance abuse and HIV/AIDS: linking the systems. Journal of Adolescent Chemical Dependency 1993;2(3/4):49-56.

Blix O, Gronbladh L. Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer N, Schmid R, Springer A, editors. Drug Addiction and AIDS. New York: Springer Verlag Wien; 1991. p. 200-205.

Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Drug paraphernalia laws and injection-related infectious disease risk among drug injectors. Journal of Drug Issues 1999;29(1):1-16.

Bluthenthal RN, Lorvick J, Kral AH, Erringer EA, Kahn JG. Collateral damage in the war on drugs: HIV behaviors among injection drug users. The International Journal of Drug Policy 1999;10:25-38.

Booth RE, Crowley T, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug and Alcohol Dependence 1996;42(1):11-20.

Booth RE, Kwiatkowski CF, Weissman G. Health-related service utilization and HIV risk behaviors among HIV infected drug users and crack smokers. Drug and Alcohol Dependence 1999;55(102):69-78.

Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, Hughes J. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Reports 1998;113(Suppl 1):42-57.

Brown LS, Burkette W, Primm BJ. Drug treatment and HIV seropositivity. New York State Journal of Medicine 1988;88(3):156.

Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J, Vincelette J. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. American Journal of Epidemiology 1997;146(12):994-1002.

Calsyn DA, Meinecke C, Saxon AJ, Stanton V. Risk reduction in sexual behavior: a condom give away program in a drug abuse treatment clinic. American Journal of Public Health 1992;82(11):1536-1538.

Calzavara L, et al. Understanding HIV-related risk behavior in prison: the inmates perspective. Toronto: University of Toronto, Faculty of Medicine, HIV Social, Behavioral and Epidemiological Studies Unit; 1997.

Capelhorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needle sharing. International Journal of Addiction 1995;30:685-698.

Carlson G, Needle R. Sponsoring addict self-organization (Addicts Against AIDS): a case study. In: The First Annual National AIDS Demonstration Research Conference; 1989; Rockville (MD).

Case P, Meehan T, Jones TS. Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18 (Suppl 1):S71-S75.

Cates W, Toomey K. Sexually transmitted diseases: overview of the situation. Primary Care 1990;17:1-27.

Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo W, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280(6):544-546.

Centers for Disease Control and Prevention, AIDS Community Demonstration Projects Research Group (CDC/ACDP). Community-level HIV intervention in five cities: final outcome data from CDC AIDS community demonstration projects. American Journal of Public Health 1999;89(3):336-345.

Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report.PDF Icon 1999a;11(2):1-45.

Centers for Disease Control and Prevention (CDC). Hepatitis B fact sheet. June 1999b.

Centers for Disease Control and Prevention (CDC). Update: syringe exchange programs-United States, 1997. Morbidity and Mortality Weekly Report 1998a;47(31):652-655.

Centers for Disease Control and Prevention (CDC). Update: HIV counseling and testing using rapid tests-United States, 1995. Morbidity and Mortality Weekly Report. 1998b Mar 27;47(11):211-215.

Centers for Disease Control and Prevention (CDC). Continued sexual risk behavior among IV-seropositive drug-using men-Atlanta; Washington, DC; San Juan, Puerto Rico, 1993. Morbidity and Mortality Weekly Report 1996;45(7):151-152.

Centers for Disease Control (CDC). Counseling and testing intravenous-drug users for HIV infection-Boston. Morbidity and Mortality Weekly Report. 1989 Jul 21;38(28):489-90, 495-496.

Centers for Disease Control (CDC). Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. Morbidity and Mortality Weekly Report 1984;33(27):377-379.

Chu A, Torbert A, Brown A, Ellison J, Matthew I, McFarland J, Forlenza S. Overlapping AIDS epidemic among injecting drug use (IDU) and heterosexual exposure (HT) in New York City (NYC) AIDS cases. 1998; 5th Conference on Retrovirology and Opportunistic Infections, February 1-5. p. 103 (Abstract No. 129).

Cohen A, Kibel B, Stewart K. Guidelines and bench marks for prevention programming. DHHS Publication No. (SMA) 95-3033. Rockville (MD): Substance Abuse and Mental Health Services Administration; 1997.

Cottler LB, Compton WM, Abdallah AB, Cunningham-Williams R, Abram F, Fichtenbaum C, Dotson W. Peer- delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public Health Reports 1998;113(Suppl 1):31-41.

Coyle SL, Needle RH, Normand J. Outre a ch-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Reports 1998;113(Suppl 1):19-30.

Crystal S, Dengelegi L, Beck P, Dejowski E. AIDS contact notification: initial program results in New Jersey. AIDS Education and Prevention. 1990;2(4):284-295.

DeLeon, G. The therapeutic community: study of effectiveness. Treatment Research Monograph 84-1286. Rockville (MD): National Institute on Drug Abuse; 1984.

Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Annals of Internal Medicine 1985;103:755-759.

Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis R, Jose B, Friedman SR. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348(9003):987-891.

Dolan KA, Wodak A, Saksena N, Dwyer D, Sorrell T. A network of HIV infection among Australian inmates. International Conference on AIDS 1996 Jul 7-12;11(2):169 (abstract no.We.D.3655).

Donovan JE, Jessor R, Costa FM. Syndrome of problem behavior in adolescence: a replication. Journal of Consulting and Clinical Psychology 1988;56(5):762-765.

Drug Strategies. Making the grade: a guide to school drug prevention programs.Link to a Non-CDC Link Washington (DC): Drug Strategies; 1999.

Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, Inciardi JA, Bowser BP, Schilling RF, Holmberg SD. Intersecting epidemics: crack cocaine use and HIV infection among inner-city adults. New England Journal of Medicine 1994;331(21):1422-1427.

El-Bassel N, Schilling RF. 15-month follow-up of women methadone patients taught skills to reduce heterosexual HIV transmission. Public Health Reports 1992;107(5):500-504.

Epstein J, Gfroerer J. Changes affecting NHSDA estimates of treatment need for 1994-1996.Link to a Non-CDC Link Washington DC: Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA); Jan 14, 1998.

Falck R, Carlson RG, Price SK, Turner JA. Case management to enhance HIV risk reduction among users of injection drugs and crack cocaine. Journal of Case Management 1994;3(4):162-166.

Farrell AD, Danish SJ, Howard CW. Relationship between drug use and other problem behaviors in urban adolescents. Journal of Consulting and Clinical Psychology 1992;60:705-712.

Fenton KA, Peterman TA. HIV partner notification: taking a new look. AIDS 1997;11(13):1535-1546.

Field G. A study of the effects of intensive treatment on reducing the criminal recidivism of addicted offenders. Federal Probation 1989; 53:51-66.

Friedman SR, Curtis R, Neaigus A, Jose B, Des Jarlais DC. Social networks, drug injectors' lives, and HIV/AIDS. New York: Kluwer/Plenum Press; 1999.

Friedman SR, Des Jarlais DC, Ward TP. Social models for changing health-relevant behavior. In: DiClemente R, Peterson J, editors. Preventing AIDS: theories and methods of behavioral interventions. New York: Plenum Press; 1994. pp. 95-116.

Friedman SR, Des Jarlais DC, Ward TP, Jose B, Neaigus A, Goldstein M. Drug injectors and heterosexual AIDS. In: Sherr L, editor. AIDS and the heterosexual population. Chur (Switzerland): Harwood Academic Publishers; 1993. pp. 41-65.

Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low sereprevalence cities. American Journal of Epidemiology 1995;142(8):864-874.

Gerstein DR, Harwood HJ, editors. Treating drug problems. Vol. I: A study of the evolution, effectiveness, and financing of public and private drug treatment systems. Washington (DC): National Academy Press; 1990.

Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users. Final results of randomized trials of counseling with and without HIV testing. AIDS & Behavior 1999;3:3-12.

Gleghorn AA, Gee G, Vlahov D. Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S89-S93.

Gleghorn AA, Jones TS, Doherty MC, Celentano DD, Vlahov D. Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10(1):97-103.

Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S60-S70.

Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler W J. Impact of increased legal access to needles and syringes on the practices of injecting-drug users and police officers- Connecticut, 1992-93. Journal of Acquired Immune Deficicency Syndromes and Human Retrovirology 1995;10(1):82-89.

Hagan H, DesJarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injecting drug users participating in the Tacoma syringe exchange program. American Journal of Public Health 1995;85(11):1531-1537.

Hahn RA, Onorato I, Jones TS, Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989;261(18):2677-2684.

Hammett TM. Public health/corrections collaborations: prevention and treatment of HIV/AIDS, STDs and TB.PDF IconLink to a Non-CDC Link (136 KB, 19 pages) Research in Brief (National Institute of Justice); July, 1998. NCJ Publication No. 169590.

Hammett TM, Harmon P, Maruschak LM. 1996-1997 update: HIV/AIDS, STDs, and TB in correctional facilities.PDF IconLink to a Non-CDC Link (562 KB, 107 pages) Issues and Practices in Criminal Justice (National Institute of Justice); July, 1999. Publication No. 176344.

Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience. Public Health Reports 1998;113(Suppl 1):107-115.

Haverkos HW. HIV/AIDS and drug abuse: epidemiology and prevention. Journal of Addictive Diseases 1998;17(4):91-103.

Health Resources and Services Administration (HRSA). Evaluation of the effects of Ryan White Title I funding on services for HIV-infected drug abusers, baseline data. Year 1: summary report. Rockville (MD): HRSA; August, 1994.

Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment 1998;15(3):1831-1891.

Heimer R, Kaplan EH, O'Keefe R, Khoshnood K, Altice F. Three years of needle exchange in New Haven: what have we learned? AIDS and Public Policy Journal 1994;9:59-73.

Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug abuse treatment: a national study of effectiveness. Chapel Hill (NC): University of North Carolina Press; 1989.

Inciardi, JA. HIV risk reduction and service delivery strategies in criminal justice settings. Journal of Substance Abuse Treatment 1996;13(5):4214-4228.

Jones J, Wykoff RF, Gamble WB, Hollis SL, Longshore ST, Gamble W, Gunn R. Partner acceptance of health department notification of HIV exposure, South Carolina. JAMA 1990;264:1284-1286.

Jose B, Friedman SR, Neaigus A, Curtis R, Sufian M, Stepherson B, Des Jarlais DC. Collective organization of injecting drug users and the struggle against AIDS. In: Rhodes T, Hartnoll R, editors. AIDS drugs and prevention: perspectives on individual and community action. New York: Routledge; 1996.

Junge B, Valente T, Latkin C, Riley E, Vlahov D. Syringe exchange not associated with social network formation: results from Baltimore. AIDS 2000 ;14(4):423-426.

Kamb ML, Fishbein M, Douglas JM, Rhodes F, Rogers J, Bolan G, Zenilman J, Hox worth T, Malotte CK, Iatesta M, Kent C, Lentz A, Graziano S, Byers RH, Peterman TA, for the Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted disease: a randomized controlled trial. JAMA 1998;280(13):1161-1167.

Kaplan R, Heimer R. HIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1992;5(2):163-169.

Keenan JM. Summary of research agenda. In: Conference proceedings of the Agency for Health Care Policy and Research (AHCPR), community-based care of persons with AIDS: developing a research agency. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service; 1990; p.169-172.

Koester SK. Copping, running, and paraphernalia laws: contextual and needle risk behavior among injection drug users in Denver. Human Organization 1994;53:287-295.

Kwiatkowski CF, Booth RE. HIV-seropositive drug users and unprotected sex. AIDS and Behavior 1998;2(2):151-159.

Landis SE, Schoenbach JJ, Weber DJ, Mittal M, Krishan MA, Lewis K, Kich GG. Results of randomized trial of partner notification in cases of HIV infection in North Carolina. New England Journal of Medicine 1992;326(2):101-106.

Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Reports 1998;113(Suppl 1):151-159.

Levy JA, Fox SE. The outreach-model of partner notification with IDUs. Public Health Reports 1998;113(Suppl 1):160-169.

Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S45-S51.

Lurie P, Reingold AL, Bowser R, Chen D, Foley J, Guydish J, et al. The public health impact of needle exchange program in the United States and abroad. San Francisco (CA): University of California, Berkeley, School of Public Health, the Institute for Health Studies; 1993.

Macalino GE, Springer KW, Rahman ZS, Vlahov D, Jones TS. Community-based programs for safe disposal of used needles and syringes. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S111-S119.

Macke BA, Maher JE. Partner notification in the United States-an evidence-based review. American Journal of Preventive Medicine 1999;17(3):230-242.

Magura S, Kang S, Shapiro JL. Outcomes of intensive AIDS education for male adolescent drug users in jail. Journal of Adolescent Health 1994;15(6):457-463.

Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in jail methadone maintenance. Journal of Drug Issues 1993;23(1):75-99.

Mahon N. New York inmates' HIV risk behaviors: the implications for prevention policy and programs. American Journal of Public Health 1996; 86(9):1211-1215.

Malow RM, West JA, Corrigan SA, Pena JM, Cunningham SC. Outcome of psychoeducation for HIV risk reduction. AIDS Education and Prevention 1994;6(2):113-125.

Marks G, Richardson J, Ruiz M, Maldonado N. HIV-infected men's practices in notifying past sexual partners of infection risk. Public Health Reports 1992;107:100-105.

McCusker J, Stoddard AM, Zapka JG, Morrison CS, Zorn M, Lewis BF. AIDS education for drug abusers: evaluation of short-term effectiveness. American Journal of Public Health 1992;82(4):533-540.

McCusker J, Stoddard AM, Zapka JG, Zorn M. Use of condoms by heterosexually active drug abusers before and after AIDS education. Sexually Transmitted Diseases 1993;20(2):81-88.

McLellan AT, Alternman AI, Metzger DS, Girssom G, Woody GE, Luborsky L, O'Brien CP. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. Journal of Consulting and Clinical Psychology 1994;62(6):1141-1158.

Meandzija B, O'Connor P, Fitzherald B, Rounsaville B, Kosten T. HIV infection and cocaine use in methadone maintained and untreated injection drug users. Drug and Alcohol Dependence 1994;36(2):109-113.

Metsch L, McCoy C, Lai S, Miles C. Continuing risk behaviors among HIV-seropositive chronic drug users in Miami, Florida. AIDS and Behavior 1998;2(2):161-169.

Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Report 1998;113(Suppl 1):97-106.

Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druly P, Navaline HA. Human immunodefiency virus seroconversion among in- and out-of-treatment intravenous drug users: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1993;6(9):1049-1056.

Moos RH. Evaluating treatment environments. New York:Wiley; 1974.

Moos RH, Rinney JW, Cronkite RC. Alcoholism treatment: context, process and outcome. New York: Oxford University Press; 1990.

Moss AR, Vranizan K, Gorter R, Bachetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco. 1985-1990. AIDS 1994;8(2):223-231.

Nabias I, Goncalves G, Quakinin S, Figueira ML. Disclosure of HIV infection to sexual partners: implications in relationship. International Conference on AIDS (Vancouver, Canada). 1996 July 7-12;11(2):351 (abstract no.Th.C.4631).

National Alliance of State and Territorial AIDS Directors (NASTAD). HIV prevention and access to sterile syringes. Joint statement issued by the American Medical Association (AMA), American Pharmaceutical Association (APhA), Association of State and Territorial Health Officials (ASTHO), National Association of Boards of Pharmacy (NABP), National Alliance of State and Territorial AIDS Directors (NASTAD). 1999 October.

National Institutes of Health (NIH). Effective medical treatment of opiate addiction.Link to a Non-CDC Link NIH Consensus Statement Online. 1997 Nov 17-19;15(6):1-38.

National Institute on Drug Abuse (NIDA). Principles of drug addiction treatment: a research-based guide.Link to a Non-CDC Link Rockville (MD): NIDA; 1999. NIH Publication No. 99-4180.

National Institute on Drug Abuse (NIDA). Preventing drug use among children and adolescents: a research-based guide.Link to a Non-CDC Link Rockville (MD): NIDA; 1997. NIH Publication No. 97-4212.

Neaigus A. The network approach and interventions to prevent HIV among injection drug users. Public Health Reports 1998;113(Suppl 1):140-150.

North RL, Rothenberg KH. Partner notification and the threat of domestic violence against women with HIV infection. New England Journal of Medicine 1993;329(16):1194-1196.

Norwood C. Mandated life versus mandatory death: New York's disgraceful partner notification record.Journal of Community Health 1995;20(2):161-170.

Novick DM, Joseph H, Croxon TS, Salsitz EA, Wang G, Richman BL, Pretsky L, Keefe JB, Whimbey E. Absence of antibody to human immunodeficiency virus in long term, social rehabilitated methadone maintenance patients. Archives of Internal Medicine 1990;150(1):97-99.

O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet 1996;347(8996):237-240.

Office of National Drug Control Policy (ONDCP). The National Youth Anti-Drug Media Campaign Communication Strategy Statement.Link to a Non-CDC Link Washington (DC): ONDCP; 1998.

Orr MF, Glebatis D, Friedmann P, Des Jarlais DC, Prevots DR. Incidence of HIV infection in a New York City methadone maintenance treatment program. JAMA 1996;276(2):99.

Osgood DW, Johnston LS, O'Malley PM, Bachman JG. The generality of deviance in late adolescence and early adult-hood. American Sociological Review 1988;53(1):81-93.

Padian NS, O'Brien TR, Chang Y, Glass S, Francis DP. Prevention of heterosexual transmission of human immunodeficiency virus through couple counseling. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1993;6(9):1043-1048.

Pavia AT, Benyo M, Niler L, Risk I. Partner notification for control of HIV: results after two years of a statewide program in Utah. American Journal of Public Health 1993;83(10):1418-1424.

Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996;12(1):69-74.

Pickens RW, Leukefeld CG, Schuster CR, editors. NIDA research monograph 106: improving drug abuse treatment. Rockville (MD): NIDA; 1991. DHHS Publication No. (ADM) 91-1754; NTIS PB#92-105873.

Prochaska JO. What causes peple to change their unhealthy to health enhancing behavior? In: Cummings CC, Gloyd J D, editors. Human behavior and cancer risk reduction: overview and report on a conference on unmet research needs. Atlanta (GA): American Cancer Society; 1989.

Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S57-S59.

Rogers SJ, Tross S, Doino-Ingersoll J, Weisfuse, I. Partner notification with HIV-infected drug users: results of formative research. AIDS Care 1998;10(4):415-429.

Rothenberg KH, Paskey SJ, Reuland MM, Zimmerman SI, North RL. Domestic violence and partner notification: implications for treatment and counseling of women with HIV. Journal of the American Medical Women's Association 1995;50(3-4):87-93.

Schechter MT, Strathdee SA, Cornelisse PGA, Currie S, Patrick DM, Rekart ML, O'Shaughnessy MV. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS 1999;13(6):F45-F51.

Schilling RF, El-Bassell N, Schinke SP, Gordoin K, Nichols D. Building skills of recovering women drug users to reduce heterosexual AIDS transmission. Public Health Reports 1991;106(3):297-304.

Semaan S, Des Jarlais DC, Sogolow ED, Ramirez G, Sweat M, Norman LM, Needle RH. A meta-analysis of the impact of HIV risk reduction interventions on safer sex behaviors of drug users. International Conference on AIDS (Geneva, Switzerland). 1998;12:232 (abstract no. 253/14250).

Serpelloni G, Carriere MP, Rezza G, Morganti S, Gomma M, Ginkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case controlled study. AIDS Care 1994;6(2):215-220.

Shoptaw S, Frosch DL, Rawson RA, Ling W. Cocaine abuse counseling as HIV prevention. AIDS Education and Prevention 1997;9(6):511-520.

Siegal HA, Glack RS, Carlson RG, Wang J. Reducing HIV needle risk behaviors among injection drug users in the midwest: an evaluation of the efficacy of standard and enhanced interventions. AIDS Education and Prevention 1995;7(4):308-319.

Simpson D, Savage L. Drug abuse treatment readmissions and outcomes: three-year follow-up of DARP patients. Archives of General Psychiatry 1980;37(8):896-901.

Singer M, Baer HA, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Reports 1998;113(Suppl 1):81-89.

Spencer NE, Hoffman RE, Raevsky CA, Wolf FC, Verson TM. Partner notification for human immunodeficiency virus infection in Colorado: results across index case groups and costs. International Journal of STD and AIDS 1993;4(1):26-32.

Springer KW, Sterk CE, Jones TS, Friedman L. Syringe disposal options for injection drug users: a community-based perspective. Substance Use and Misuse 1999;34(13): 1917-1934.

Strathdee SA, Patrick DM, Currie SL, Cornelisse P, Rekart M, Montaner J, Schechter MT, O'Shaughnessy M. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11(8):F59-F65.

Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281:1000-1005.

Struckman-Johnson C, Struckman-Johnson D, Rucker L, Bumby K, Donaldson S. Sexual coercion reported by men and women in prison. Journal of Sex Research 1996;33(1):67-76.

Sufian M, Friedman SR, Curtis R, Neaigus A, Stepherson B. Organizing as a new approach to AIDS risk reduction for intravenous drug users. Journal of Addictive Diseases 1991;10(4):89-98.

Sumartojo E, Carey JW, Doll LS, Gayle H. Targeted and general population interventions for HIV prevention: towards a comprehensive approach. AIDS 1997;11(10):1201-1209.

Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies needle and syringe sales- Connecticut, 1992-1993. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10(1):73-81.

Vanichseni S, DesJarlais DC, Choopanya K, Friedmann P, Wenston J, Sonchai W, Sotheran JL, Rakthan S, Carballo M, Friedman SR. Condom use with primary partners among injecting drug users in Bangkok, Thailand and New York City, USA. AIDS 1993;7(6):887-891.

Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Reports 1998;113(Suppl 1):75-80.

Vlahov D, Junge B, Brookmeyer R, Cohn S, Riley E, Armenian H, Beilenson P. Reductions in high risk drug use behaviors among participants in the Baltimore needle exchange program. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997;16(5):400-406.

Waldron K, Hersh J, Rankin JT. Notification of syringe-sharing and sex partners of HIV-infected persons- Pennsylvania, 1993-1994. Morbidity and Mortality Weekly Report 1995;44(11):202-204.

Watters J, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271(2):115-120.

Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. American Journal of Public Health 1999;89(9):1397-1405.

Weinstein B, Toce P, Katz D, Ryan LL. Peer education of pharmacists and supplying pharmacies with IDU packets to increase injection drug users access to sterile syringes in Connecticut. [letter] Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S146-S147.

Weismann G, Brown V. Drug-using women and HIV. In: O'Leary A, Jemmott LS, editors. Women at risk: issues in the primary prevention of AIDS. New York: Plenum Press; 1995. pp.175-193.

Weissman G, Melchior L, Huba G, Smereck G, Needle, R, McCarthy S, Jones A, Genser S, Cottler L, Booth R, Altice F. Women living with drug abuse and HIV disease: drug abuse treatment access and secondary prevention issues . Journal of Psychoactive Drugs 1995;27(4):401-411.

West GR, Stark KA. Partner notification for HIV prevention: a critical reexamination. AIDS Education and Prevention 1997;9(Suppl B):68-78.

Wexler HK, Magura S, Beardsley MM, Josepher H. ARRIVE: an AIDS education/relapse prevention model for high-risk parolees. International Journal of Addictions 1994;29(3):361-386.

Whiticar P, Smetka S. Peer outreach to IDUs in rural Hawaii. Presentation at the National HIV Prevention Conference, Atlanta (GA). August 29-September 1, 1999.

Wiebel WW, Jimenez A, Johnson W, Ouellet L, Jovanovic B, Lampinen T, Murray J, O'Brien MU. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996;12(3):282-289.

Williams AB, McNelly EA, Williams AE, D'Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injection drug users. AIDS Care 1992;4(1):35-41.

Wolitski RJ, MacGowan RJ, Higgins DL, Jorgensen CM. The effects of HIV counseling and testing on risk-related practices and help-seeking behavior. AIDS Education and Prevention 1997;9(Suppl B):52-67.

Wright-De AgŁero L, Weinstein B, Jones TS, Miles J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practice. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S102-S110.

Wykoff RF, Jones JL, Longshore ST, Hollis SL, Quiller CB, Dowda H, Gamble WB. Notification of the sex and needle-sharing partners of individuals with human immunodeficiency virus in rural South Carolina: 30 month experience. Sexually Transmitted Diseases 1991;18(4):217-222.

View PDFPDF Icon

Previous Page | Table of Contents | Next Page

This CDC Web site is no longer being reviewed or updated and thus is no longer kept current. This site remains to assist researchers or others needing historical content.

Go to top

Privacy Policy | Accessibility The U.S. Government's Official Web Portal